The oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions yesterday announced it has entered into a partnership with Tabula Rasa HealthCare® (TRHC) (NASDAQ: TRHC), a healthcare technology Company advancing the field of medication safety. Through this initiative, Physiomics' personalised docetaxel model will be integrated into TRHC's market-leading precision dosing solution, DoseMeRx®. Both parties expect positiv ....
18 Dec 2020
Partnership with Tabula Rasa HealthCare’s DoseMeRx® for personalised docetaxel model and further Merck contracts.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Partnership with Tabula Rasa HealthCare’s DoseMeRx® for personalised docetaxel model and further Merck contracts.
Physiomics Plc (PYC:LON) | 1.4 0 (-3.3%) | Mkt Cap: 1.96m
- Published:
18 Dec 2020 -
Author:
Derren Nathan -
Pages:
7
The oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions yesterday announced it has entered into a partnership with Tabula Rasa HealthCare® (TRHC) (NASDAQ: TRHC), a healthcare technology Company advancing the field of medication safety. Through this initiative, Physiomics' personalised docetaxel model will be integrated into TRHC's market-leading precision dosing solution, DoseMeRx®. Both parties expect positiv ....